Cell culture studies of the efficacy and barrier to resistance of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir against hepatitis C virus genotypes 2a, 2b and 2c
Antimicrobial agents and chemotherapy, 2019.
Introduction of highly efficient therapies with direct-acting antivirals (DAA) for patients with chronic hepatitis C virus (HCV) infection offers exceptional opportunities to globally control this deadly disease. For achieving this ambitious goal, it is essential to prevent antiviral resistance against the most optimal first-line and retr...More
Full Text (Upload PDF)